Page last updated: 2024-12-09

epalrestat

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

epalrestat : A monocarboxylic acid that is 1,3-thiazolidine which is substituted on the nitrogen by a carboxymethyl group, at positions 2 and 4 by thioxo and oxo groups, respectively, and at position 5 by a 2-methyl-3-phenylprop-2-en-1-ylidene group. It is an inhibitor of aldose reductase (which catalyses the conversion of glucose to sorbitol) and is used for the treatment of some diabetic complications, including neuropathy. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1549120
CHEMBL ID56337
CHEBI ID31539
SCHEMBL ID49049
MeSH IDM0114923

Synonyms (69)

Synonym
2-(5-(2-methyl-3-phenylallylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid
bdbm50049730
2-[(5z)-5-[(e)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid
ono-2235
epalrestat
kinedak
epalrestat (jp17/inn)
kinedak (tn)
82159-09-9
D01688
MLS000806985
smr000414799
{5-[(e)-2-methyl-3-phenyl-prop-2-en-(z)-ylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid
NCGC00164613-01
epalrestat [inn]
epalrestatum [latin]
ono 2235
3-thiazolidineacetic acid, 5-(2-methyl-3-phenyl-2-propenylidene)-4-oxo-2-thioxo-, (e,e)-
5-((z,e)-beta-methylcinnamylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid
5-((1z,2e)-2-methyl-3-phenylpropenylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid
ono-2
ono 2
STK337187
{(5z)-5-[(2e)-2-methyl-3-phenylprop-2-en-1-ylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl}acetic acid
AKOS000274207
CHEMBL56337 ,
aldorin
tanglin
chebi:31539 ,
aldonil
[5-(2-methyl-3-phenyl-allylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid
unii-424dv0807x
424dv0807x ,
epalrestatum
dtxsid1046479 ,
BCP9000649
2-((z)-5-((e)-2-methyl-3-phenylallylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid
(5-[(e)-2-methyl-3-phenyl-prop-2-en-(z)-ylidene]-4-oxo-2-thioxo-thiazolidin-3-yl)-acetic acid 82159-
HMS2747M09
BCP0726000053
epalrestat [who-dd]
epalrestat [mi]
epalrestat [mart.]
epalrestat [jan]
5-((z,e)-.beta.-methylcinnamylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid
S2035
HY-66009
SCHEMBL49049
2-[(5z)-5-[(2e)-2-methyl-3-phenylprop-2-en-1-ylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid
E0906
BBL029067
REGID_FOR_CID_1549120
CHNUOJQWGUIOLD-NFZZJPOKSA-N
AB00647195_06
ono2235
mfcd00865484
SW219826-1
2-[(5z)-5-[(e)-3-phenil-2-methylprop-2-enylidene]-4-oxo-2-thioxo-3-thiazolidinyl]acetic acid
Q5382029
5-[(1z, 2e)-2-methyl-3-phenylpropenylidene]-4-oxo2-thioxo-3-thiazolidineacetic acid
DB15293
AS-13345
NCGC00164613-12
HMS3887A17
CCG-267693
NCGC00164613-08
gtpl11371
epalrestat- bio-x
BE164412

Research Excerpts

Overview

Etalrestat is a safe, oral and brain penetrant drug that was approved 27 years ago in Japan to treat diabetic neuropathy. Epalrestat (EPL) is a water-insoluble drug (14μM) that inhibits aldose reductase.

ExcerptReferenceRelevance
"Epalrestat (EPA) is a potent inhibitor of aldose reductases AKR1B1 and AKR1B10, used for decades in Japan for the treatment of diabetic peripheral neuropathy. "( Moving toward a new horizon for the aldose reductase inhibitor epalrestat to treat drug-resistant cancer.
Bailly, C, 2022
)
2.4
"Epalrestat is a safe, oral and brain penetrant drug that was approved 27 years ago in Japan to treat diabetic neuropathy in geriatric populations."( Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG.
DiPrimio, N; Iyer, S; Lao, J; Morava, E; Murthy, K; Parton, Z; Perlstein, EO; Preston, G; Sam, FS; Tsang, H; Verheijen, J, 2019
)
1.47
"Epalrestat (EPS) is a brain penetrant aldose reductase inhibitor, an approved drug currently used for the treatment of diabetic neuropathy. "( Neuroprotective Effect of Epalrestat on Hydrogen Peroxide-Induced Neurodegeneration in SH-SY5Y Cellular Model.
Lingappa, S; Manivasagam, T; Seedevi, P; Shivakumar, MS; Somasundaram, ST, 2021
)
2.36
"Epalrestat (EPL) is a water-insoluble drug (14μM) that inhibits aldose reductase. "( Enhanced dissolution and skin permeation profiles of epalrestat with β-cyclodextrin derivatives using a cogrinding method.
Endo, T; Furuishi, T; Gunji, M; Nagase, H; Ogawa, N; Suzuki, T; Takahashi, S; Tomono, K; Ueda, H; Yonemochi, E, 2017
)
2.15
"Epalrestat is an inhibitor of aldose reductase in the polyol pathway and is used for the management of diabetic neuropathy clinically. "( The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation.
Aa, JY; Ding, F; Gao, HX; He, J; Sun, RB; Wang, GJ; Wang, JK; Xie, Y; Yang, N; Zeng, CH; Zhang, JW; Zhu, XD, 2019
)
2.24
"Epalrestat (Kinedak) is an aldose reductase inhibitor (ARI) for diabetic peripheral neuropathy. "( [Examination of questionnaires regarding diabetic peripheral neuropathy in epalrestat-treated patients and their usefulness in the treatment of the patients during the treatment course].
Atarashi, H; Ibuki, C; Ishii-Nozawa, R; Ito, A; Kataoka, H; Takeuchi, K, 2009
)
2.03
"Epalrestat is an aldose reductase inhibitor that is approved in Japan for the improvement of subjective neuropathy symptoms, abnormality of vibration sense, and abnormal changes in heart beat associated with diabetic peripheral neuropathy."( Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
Borja, NL; Ramirez, MA, 2008
)
2.51
"Epalrestat is a carboxylic acid derivative which inhibits aldose reductase, an enzyme of the sorbitol (polyol) pathway. "( Epalrestat. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus.
Faulds, D; Goa, KL; Steele, JW,
)
3.02

Treatment

epalrestat treatment, which started 4 weeks after STZ injection, resulted in a significantly greater NGF content and faster HSNCV than those in untreated diabetic rats. Pre-treatment with epalRestat completely prevented the increased urinary excretion of NAG, AAP and GGT.

ExcerptReferenceRelevance
"The epalrestat treatment, which started 4 weeks after STZ injection, resulted in a significantly greater NGF content and faster HSNCV than those in untreated diabetic rats."( Therapeutic effects of aldose reductase inhibitor on experimental diabetic neuropathy through synthesis/secretion of nerve growth factor.
Furukawa, S; Hayashi, K; Matsukura, S; Ohi, T; Ohta, M; Saita, K, 1998
)
0.78
"Pretreatment with epalrestat, or a selective inhibitor of AKR1B10, exacerbated TKI-induced cell death, suggesting that especially AKR1B10 was involved in protection against TKIs."( Aldo-keto reductase inhibitors increase the anticancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia.
Aoki, S; Endo, S; Furuichi, K; Hirao, T; Ito, K; Kikuya, M; Toyooka, N, 2021
)
0.94
"Pretreatment with epalrestat prior to high glucose exposure resulted in elevated eNOS mRNA and protein expression levels and NO up-regulation in the cell culture as compared with the glucose exposure alone group (P<0.05), causing also decreased expression of AR and NOX4 in the cells."( [Protective effect of epalrestat against high glucose-induced endothelial cell injuries].
Hong, Q; Liu, G; Wang, F, 2012
)
1.02
"Treatment with epalrestat had no significant effect on incremental changes in erythrocyte sorbitol and F3P content following fructose ingestion."( Effects of fructose ingestion on sorbitol and fructose 3-phosphate contents of erythrocytes from healthy men.
Fujii, T; Fujinami, T; Ito, J; Kamiya, Y; Kawaguchi, M; Okada, M; Sakuma, N, 1996
)
0.63
"Pre-treatment with epalrestat completely prevented the increased urinary excretion of NAG, AAP and GGT."( Effects of renal sorbitol accumulation on urinary excretion of enzymes in hyperglycaemic rats.
Aoki, Y; Ikenaga, H; Ishii, N; Ogawa, Z; Saruta, T; Suga, T, 2001
)
0.63

Pharmacokinetics

ExcerptReferenceRelevance
" Validated method was applied to analyze rat plasma samples obtained from a pharmacokinetic study."( LC-MS/MS method for the quantification of aldose reductase inhibitor-epalrestat and application to pharmacokinetic study.
Ajjala, DR; Bhyrapuneni, G; Kandikere, V; Muddana, NR; Nirogi, R, 2013
)
0.62
"In the present study, a simple, rapid and reliable ultrahigh-performance liquid chromatography-tandem mass spectrometric (UHPLC-MS/MS) method was developed and validated to determine simultaneously epalrestat (EPA) and puerarin (PUE) in rat plasma for evaluation of the pharmacokinetic interaction of these two drugs."( Simultaneous determination of epalrestat and puerarin in rat plasma by UHPLC-MS/MS: Application to their pharmacokinetic interaction study.
Bo, Y; Sun, H; Wu, X; Xiong, Z; Zhang, M; Zhao, L; Zhou, M, 2017
)
0.93

Compound-Compound Interactions

Etalrestat combined with α-lipoic acid (ALA) is the most frequent combine therapy used in the DPN researches. This review will evaluate the total effective rate, nerve conduction velocity, TCSS, TSS and safety of ALA combined with epalrestat.

ExcerptReferenceRelevance
"Objective To compare the clinical effectiveness of lipoic acid combined with epalrestat versus lipoic acid in treating diabetic peripheral neuropathy(DPN)."( Lipoic Acid Combined with Epalrestat versus Lipoic Acid in Treating Diabetic Peripheral Neuropathy:A Meta-analysis.
Lin, HX; Lu, YK; Wang, XT; Xu, SA, 2017
)
0.98
" Epalrestat combined with α-lipoic acid (ALA) is the most frequent combine therapy used in the DPN researches."( The clinical efficacy of epalrestat combined with α-lipoic acid in diabetic peripheral neuropathy: Protocol for a systematic review and meta-analysis.
Jin, Y; Lin, H; Wang, X; Xu, S; Zhang, R, 2018
)
1.69
"This review will evaluate the total effective rate, nerve conduction velocity, TCSS, TSS, and safety of ALA combined with epalrestat for patients with DPN, compare with epalrestat alone."( The clinical efficacy of epalrestat combined with α-lipoic acid in diabetic peripheral neuropathy: Protocol for a systematic review and meta-analysis.
Jin, Y; Lin, H; Wang, X; Xu, S; Zhang, R, 2018
)
0.99
"Our study will provide evidence to assess whether epalrestat combined with ALA is an optional treatment for patients with DPN."( The clinical efficacy of epalrestat combined with α-lipoic acid in diabetic peripheral neuropathy: Protocol for a systematic review and meta-analysis.
Jin, Y; Lin, H; Wang, X; Xu, S; Zhang, R, 2018
)
1.04

Bioavailability

The aim of this study was to estimate in vivo permeability and bioavailability of epalrestat and newly synthesized compounds with possible therapeutic activity as aldose enzyme inhibitors (ARIs)

ExcerptReferenceRelevance
"The aim of this study was to estimate in vivo permeability and bioavailability of epalrestat and newly synthesized compounds with possible therapeutic activity as aldose enzyme inhibitors (ARIs)."( Permeability characteristics of novel aldose reductase inhibitors using rat jejunum in vitro.
Demopoulos, VJ; Kristl, A; Levstik, L; Sturm, K, 2006
)
0.56
" Bioavailability was found to be 90 ± 14% for epalrestat in male wistar rats."( LC-MS/MS method for the quantification of aldose reductase inhibitor-epalrestat and application to pharmacokinetic study.
Ajjala, DR; Bhyrapuneni, G; Kandikere, V; Muddana, NR; Nirogi, R, 2013
)
0.88
" Prolonged circulation half-life and tumor site bioavailability were achieved for both the drugs with the developed approach."( Targeted co-delivery of the aldose reductase inhibitor epalrestat and chemotherapeutic doxorubicin via a redox-sensitive prodrug approach promotes synergistic tumor suppression.
Banala, VT; Dwivedi, M; Gautam, S; Marwaha, D; Mishra, PR; Sharma, M; Sharma, S; Shukla, RP; Urandur, S, 2019
)
0.76

Dosage Studied

ExcerptRelevanceReference
"Most treatments for diabetic eye conditions rely on systemic (oral) or intravitreal administration, and there is still a demand of efficient and comfortable ocular dosage forms."( Epalrestat-loaded silicone hydrogels as contact lenses to address diabetic-eye complications.
Alvarez-Lorenzo, C; Alvarez-Rivera, F; Concheiro, A, 2018
)
1.92
"Transdermal penetration of therapeutic moieties from topical dosage forms always remains a challenge due to the presence of permeation impeding keratin which should be addressed."( Exploring the Potent Combination of Quercetin-Boronic Acid, Epalrestat, and Urea Containing Nanoethosomal Keratolytic Gel for the Treatment of Diabetic Neuropathic Pain: In Vitro and In Vivo Studies.
Abid, S; Ameer, N; Azeem, M; Danish, Z; Hanif, M; Khan, M; Khurshid, U; Mahmood, K; Pandey, K; Qaiser, M; Razaque, G; Sajid Chughtai, FR; Usman Abid, HM, 2023
)
1.15
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
EC 1.1.1.21 (aldehyde reductase) inhibitorAn EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor) inhibitor that interferes with the action of aldehyde reductase (EC 1.1.1.21).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
thiazolidines
monocarboxylic acidAn oxoacid containing a single carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (33)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency19.90540.140911.194039.8107AID2451
LuciferasePhotinus pyralis (common eastern firefly)Potency11.68410.007215.758889.3584AID588342; AID624030
ATAD5 protein, partialHomo sapiens (human)Potency18.34890.004110.890331.5287AID504467
GLS proteinHomo sapiens (human)Potency35.48130.35487.935539.8107AID624170
Microtubule-associated protein tauHomo sapiens (human)Potency7.94330.180013.557439.8107AID1460
P53Homo sapiens (human)Potency70.79460.07319.685831.6228AID504706
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency3.54810.01262.451825.0177AID485313
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency62.05060.354828.065989.1251AID504847
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency26.67950.168316.404067.0158AID720504
DNA polymerase eta isoform 1Homo sapiens (human)Potency79.43280.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency25.11890.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency28.30380.004611.374133.4983AID624296
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency14.38180.005612.367736.1254AID624032
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency35.48130.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency31.62280.891312.067628.1838AID1487
Rap guanine nucleotide exchange factor 3Homo sapiens (human)Potency89.12516.309660.2008112.2020AID720709
Rap guanine nucleotide exchange factor 4Homo sapiens (human)Potency56.23413.981146.7448112.2020AID720708
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
high affinity choline transporter 1 isoform aHomo sapiens (human)IC50 (µMol)7.96350.00036.210228.8403AID504840; AID588401
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)45.80000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)6.50000.20005.677410.0000AID1473741
Aldo-keto reductase family 1 member B10Homo sapiens (human)IC50 (µMol)0.18360.00101.94459.6000AID1646337; AID1646338; AID489631; AID643317
Bile salt export pumpHomo sapiens (human)IC50 (µMol)36.80000.11007.190310.0000AID1473738
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)IC50 (µMol)0.55960.00041.877310.0000AID1060596; AID1143067; AID1202885; AID1242917; AID1298952; AID1366743; AID1436864; AID1589443; AID1589449; AID1589454; AID1589459; AID1603210; AID1603211; AID1659473; AID1678096; AID1732108; AID1732109; AID335838; AID34193; AID34795; AID34806; AID34961; AID34963; AID34964; AID385353; AID641150; AID654333; AID654479
Aldo-keto reductase family 1 member A1Homo sapiens (human)IC50 (µMol)2.60000.00502.78569.9000AID489639; AID643314
Aldo-keto reductase family 1 member B1Homo sapiens (human)IC50 (µMol)1.16400.00101.191310.0000AID1338272; AID1463380; AID1529987; AID1589441; AID1646332; AID1646335; AID1646336; AID1713572; AID35131; AID489638; AID516862; AID643316
Aldo-keto reductase family 1 member B1Bos taurus (cattle)IC50 (µMol)0.17000.00702.589210.0000AID1143289; AID549694
Cytochrome P450 2C19Homo sapiens (human)IC50 (µMol)0.08500.00002.398310.0000AID1338272
Aldo-keto reductase family 1 member A1Sus scrofa (pig)IC50 (µMol)1.50000.00051.66804.0000AID34179
Aldo-keto reductase family 1 member A1Rattus norvegicus (Norway rat)IC50 (µMol)1.50000.02801.13782.3200AID34192
Enoyl-[acyl-carrier-protein] reductase [NADH]Mycobacterium tuberculosis H37RvIC50 (µMol)200.00000.03002.286410.0000AID1639206
Sorbitol dehydrogenaseHomo sapiens (human)IC50 (µMol)67.70000.24000.49531.0000AID516864
Aldo-keto reductase family 1 member B7Rattus norvegicus (Norway rat)IC50 (µMol)1.19800.04900.62351.1980AID1678095
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)84.40002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (100)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
farnesol catabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
cellular detoxification of aldehydeAldo-keto reductase family 1 member B10Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 3Homo sapiens (human)
signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 3Homo sapiens (human)
associative learningRap guanine nucleotide exchange factor 3Homo sapiens (human)
Rap protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
intracellular signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of GTPase activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of protein export from nucleusRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of stress fiber assemblyRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
establishment of endothelial barrierRap guanine nucleotide exchange factor 3Homo sapiens (human)
cellular response to cAMPRap guanine nucleotide exchange factor 3Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 3Homo sapiens (human)
lipid metabolic processAldo-keto reductase family 1 member A1Homo sapiens (human)
glucuronate catabolic process to xylulose 5-phosphateAldo-keto reductase family 1 member A1Homo sapiens (human)
L-ascorbic acid biosynthetic processAldo-keto reductase family 1 member A1Homo sapiens (human)
D-glucuronate catabolic processAldo-keto reductase family 1 member A1Homo sapiens (human)
negative regulation of apoptotic processAldo-keto reductase family 1 member A1Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member A1Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member A1Homo sapiens (human)
aldehyde catabolic processAldo-keto reductase family 1 member A1Homo sapiens (human)
cellular detoxification of aldehydeAldo-keto reductase family 1 member A1Homo sapiens (human)
glutathione derivative biosynthetic processAldo-keto reductase family 1 member A1Homo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
epithelial cell maturationAldo-keto reductase family 1 member B1Homo sapiens (human)
renal water homeostasisAldo-keto reductase family 1 member B1Homo sapiens (human)
carbohydrate metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
C21-steroid hormone biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
L-ascorbic acid biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
regulation of urine volumeAldo-keto reductase family 1 member B1Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
negative regulation of apoptotic processAldo-keto reductase family 1 member B1Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
fructose biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
cellular hyperosmotic salinity responseAldo-keto reductase family 1 member B1Homo sapiens (human)
metanephric collecting duct developmentAldo-keto reductase family 1 member B1Homo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member B1Bos taurus (cattle)
prostaglandin metabolic processAldo-keto reductase family 1 member B1Bos taurus (cattle)
retinol metabolic processAldo-keto reductase family 1 member B1Bos taurus (cattle)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
glucose metabolic processSorbitol dehydrogenaseHomo sapiens (human)
sorbitol catabolic processSorbitol dehydrogenaseHomo sapiens (human)
glucuronate catabolic process to xylulose 5-phosphateSorbitol dehydrogenaseHomo sapiens (human)
flagellated sperm motilitySorbitol dehydrogenaseHomo sapiens (human)
fructose biosynthetic processSorbitol dehydrogenaseHomo sapiens (human)
L-xylitol catabolic processSorbitol dehydrogenaseHomo sapiens (human)
L-xylitol metabolic processSorbitol dehydrogenaseHomo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
calcium-ion regulated exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
positive regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of synaptic vesicle cycleRap guanine nucleotide exchange factor 4Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (70)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
retinal dehydrogenase activityAldo-keto reductase family 1 member B10Homo sapiens (human)
aldo-keto reductase (NADPH) activityAldo-keto reductase family 1 member B10Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member B10Homo sapiens (human)
alcohol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B10Homo sapiens (human)
geranylgeranyl reductase activityAldo-keto reductase family 1 member B10Homo sapiens (human)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B10Homo sapiens (human)
indanol dehydrogenase activityAldo-keto reductase family 1 member B10Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B10Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member B10Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein domain specific bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
all-trans-retinol dehydrogenase (NAD+) activityAldo-keto reductase family 1 member A1Homo sapiens (human)
aldo-keto reductase (NADPH) activityAldo-keto reductase family 1 member A1Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member A1Homo sapiens (human)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member A1Homo sapiens (human)
L-glucuronate reductase activityAldo-keto reductase family 1 member A1Homo sapiens (human)
glucuronolactone reductase activityAldo-keto reductase family 1 member A1Homo sapiens (human)
glycerol dehydrogenase [NADP+] activityAldo-keto reductase family 1 member A1Homo sapiens (human)
S-nitrosoglutathione reductase (NADH) activityAldo-keto reductase family 1 member A1Homo sapiens (human)
S-nitrosoglutathione reductase (NADPH) activityAldo-keto reductase family 1 member A1Homo sapiens (human)
methylglyoxal reductase (NADPH) (acetol producing) activityAldo-keto reductase family 1 member A1Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member A1Homo sapiens (human)
retinal dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member B1Homo sapiens (human)
electron transfer activityAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin H2 endoperoxidase reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glyceraldehyde oxidoreductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
L-glucuronate reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glycerol dehydrogenase [NADP+] activityAldo-keto reductase family 1 member B1Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
retinal dehydrogenase activityAldo-keto reductase family 1 member B1Bos taurus (cattle)
prostaglandin H2 endoperoxidase reductase activityAldo-keto reductase family 1 member B1Bos taurus (cattle)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B1Bos taurus (cattle)
glycerol dehydrogenase [NADP+] activityAldo-keto reductase family 1 member B1Bos taurus (cattle)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B1Bos taurus (cattle)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
(R,R)-butanediol dehydrogenase activitySorbitol dehydrogenaseHomo sapiens (human)
L-iditol 2-dehydrogenase activitySorbitol dehydrogenaseHomo sapiens (human)
zinc ion bindingSorbitol dehydrogenaseHomo sapiens (human)
carbohydrate bindingSorbitol dehydrogenaseHomo sapiens (human)
identical protein bindingSorbitol dehydrogenaseHomo sapiens (human)
D-xylulose reductase activitySorbitol dehydrogenaseHomo sapiens (human)
D-sorbitol dehydrogenase (acceptor) activitySorbitol dehydrogenaseHomo sapiens (human)
ribitol 2-dehydrogenase activitySorbitol dehydrogenaseHomo sapiens (human)
NAD bindingSorbitol dehydrogenaseHomo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein-macromolecule adaptor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
small GTPase bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (35)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
extracellular regionAldo-keto reductase family 1 member B10Homo sapiens (human)
lysosomeAldo-keto reductase family 1 member B10Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B10Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B10Homo sapiens (human)
mitochondrionAldo-keto reductase family 1 member B10Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
cortical actin cytoskeletonRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
microvillusRap guanine nucleotide exchange factor 3Homo sapiens (human)
endomembrane systemRap guanine nucleotide exchange factor 3Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
lamellipodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
filopodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular exosomeRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular spaceAldo-keto reductase family 1 member A1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member A1Homo sapiens (human)
synapseAldo-keto reductase family 1 member A1Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member A1Homo sapiens (human)
apical plasma membraneAldo-keto reductase family 1 member A1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member A1Homo sapiens (human)
extracellular spaceAldo-keto reductase family 1 member B1Homo sapiens (human)
nucleoplasmAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
extracellular spaceSorbitol dehydrogenaseHomo sapiens (human)
cytosolSorbitol dehydrogenaseHomo sapiens (human)
membraneSorbitol dehydrogenaseHomo sapiens (human)
motile ciliumSorbitol dehydrogenaseHomo sapiens (human)
mitochondrial membraneSorbitol dehydrogenaseHomo sapiens (human)
extracellular exosomeSorbitol dehydrogenaseHomo sapiens (human)
cytosolRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (174)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1463380Inhibition of aldose reductase (unknown origin)2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
1-Acetyl-5-phenyl-1H-pyrrol-3-ylacetate: An aldose reductase inhibitor for the treatment of diabetic nephropathy.
AID1464666Inhibition of Sprague-Dawley rat lenses ALR2 using DL-glyceraldehyde as substrate pretreated for 10 mins followed by substrate addition measured for 5 mins by spectrophotometric analysis2017Bioorganic & medicinal chemistry letters, 10-15, Volume: 27, Issue:20
Quinazolinone-based rhodanine-3-acetic acids as potent aldose reductase inhibitors: Synthesis, functional evaluation and molecular modeling study.
AID1892593Octanol/buffer distribution coefficient, log D of compound at pH 7.4 incubated for 24 hrs by shake flask based HPLC method2022Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13
Novel Hydroxychalcone-Based Dual Inhibitors of Aldose Reductase and α-Glucosidase as Potential Therapeutic Agents against Diabetes Mellitus and Its Complications.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID489640Selectivity ratio of IC50 for human AR to IC50 for AKR1B102010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.
AID1589446Inhibition of ALR2 in rat erythrocytes assessed as reduction in sorbitol accumulation at 1 uM incubated for 3 hrs in presence of 28 mM glucose by gas chromatographic analysis relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis of new arylsulfonylspiroimidazolidine-2',4'-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress.
AID1202888Inhibition of Wistar rat kidney aldehyde reductase using D-glucuronate as substrate by spectrophotometry2015Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6
Identification of novel aldose reductase inhibitors based on carboxymethylated mercaptotriazinoindole scaffold.
AID1772559Inhibition of ALR1 in Wistar rat kidney assessed as reduction in NADPH consumption using sodium D-glucuronate and NADPH as substrate preincubated for 1 mins followed by substrate addition and measured upto 4 mins by spectrophotometric analysis2021European journal of medicinal chemistry, Nov-05, Volume: 223Non-carboxylic acid inhibitors of aldose reductase based on N-substituted thiazolidinedione derivatives.
AID1197494Inhibition of Wistar rat lenses ALR2 using D,L-glyceraldehyde as substrate preincubated for 10 mins before substrate addition measured after 5 mins by spectrophotometry2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Design and synthesis of potent and multifunctional aldose reductase inhibitors based on quinoxalinones.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1298952Inhibition of ALR2 from rat lens using D,L-glyceraldehyde as substrate measured as absorption of NADPH for 4 mins by UV/vis spectrophotmetry2016Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12
Synthesis of benzothiadiazine derivatives exhibiting dual activity as aldose reductase inhibitors and antioxidant agents.
AID1463387Cytoprotective activity against HG-induced cell death in rat HBZY-1 cells assessed as increase in apoptosis at 0.9 uM by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 2.83 No_unit)2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
1-Acetyl-5-phenyl-1H-pyrrol-3-ylacetate: An aldose reductase inhibitor for the treatment of diabetic nephropathy.
AID654333Inhibition of Sprague-Dawley rat lens aldose reductase2012Journal of natural products, Feb-24, Volume: 75, Issue:2
Chemical constituents from the aerial parts of Aster koraiensis with protein glycation and aldose reductase inhibitory activities.
AID1892597Antidiabetic activity against STZ-induced diabetic Sprague-Dawley rat model assessed as reduction in fasting blood glucose level at 80 mg/kg, IG administered once daily for 28 days2022Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13
Novel Hydroxychalcone-Based Dual Inhibitors of Aldose Reductase and α-Glucosidase as Potential Therapeutic Agents against Diabetes Mellitus and Its Complications.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1197891Inhibition of aldose reductase (unknown origin) at 10 ug/ml2015European journal of medicinal chemistry, Mar-06, Volume: 92Chalcones and their therapeutic targets for the management of diabetes: structural and pharmacological perspectives.
AID1589466Cytotoxicity against HEK293 cells assessed as reduction in cell viability at 25 uM incubated for 48 hrs by MTT assay relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis of new arylsulfonylspiroimidazolidine-2',4'-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID709674Inhibition of Sprague-Dawley albino rat kidney Aldehyde reductase by spectrophotometry2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Benzofuroxane derivatives as multi-effective agents for the treatment of cardiovascular diabetic complications. Synthesis, functional evaluation, and molecular modeling studies.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID381851Apparent permeability from mucosal to serosal side in Wistar rat jejunum2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Design and synthesis of N-(3,5-difluoro-4-hydroxyphenyl)benzenesulfonamides as aldose reductase inhibitors.
AID1366758Inhibition of ALR2 in Wistar rat lens assessed as reduction in glucose induced-sorbitol accumulation by measuring sorbitol level at 50 uM preincubated for 30 mins followed by glucose addition measured after 3 hrs by resazurin dye based fluorescence assay 2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Structure optimization of tetrahydropyridoindole-based aldose reductase inhibitors improved their efficacy and selectivity.
AID1732119Antioxidant activity in STZ-induced diabetic Kunming mouse assessed as reduction in liver MDA level at 80 mg/kg, po administered daily via gavage for 8 weeks and measured at 6 hrs post-final drug dose relative to STZ-treated group2021European journal of medicinal chemistry, Apr-05, Volume: 215Multifunctional agents based on benzoxazolone as promising therapeutic drugs for diabetic nephropathy.
AID1732156Reno-protective activity in STZ-induced Kunming mouse model of diabetes assessed as reduction in urinary total protein excretion at 80 mg/kg, po administered daily via gavage for 8 weeks and measured at week 8 relative to control2021European journal of medicinal chemistry, Apr-05, Volume: 215Multifunctional agents based on benzoxazolone as promising therapeutic drugs for diabetic nephropathy.
AID1646332Inhibition of human recombinant AKR1B1 assessed as D,L-glyceraldehyde reduction incubated in sodium phosphate buffer at pH 6.2 in presence of NADPH2020Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2
Early identification of promiscuous attributes of aldose reductase inhibitors using a DMSO-perturbation assay.
AID643314Inhibition of human recombinant AKR1A1 expressed in Escherichia coli BL21 cells using D-glucuronate as substrate by spectrophotometry2012Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1
Design, synthesis, and biological evaluation of novel (1-thioxo-1,2,3,4-tetrahydro-β-carbolin-9-yl)acetic acids as selective inhibitors for AKR1B1.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID489642Selectivity ratio of IC50 for human ALR to IC50 for human AR2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.
AID1436864Inhibition of rat lens ALR2 using D,L-glyceraldehyde as substrate assessed as decrease in NADPH oxidation preincubated for 10 mins followed by substrate addition measured for 4 mins by spectrophotometer2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
Synthesis and structure-activity relationship studies of phenolic hydroxyl derivatives based on quinoxalinone as aldose reductase inhibitors with antioxidant activity.
AID1589457Inhibition of ALR2 in rat lens assessed as reduction in sorbitol accumulation at 10 uM incubated for 3 hrs in presence of 28 mM glucose by gas chromatographic analysis relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis of new arylsulfonylspiroimidazolidine-2',4'-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1473944Ratio of drug concentration at steady state in human at 50 mg, po QD after 24 hrs to IC50 for human MRP3 overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1639206Inhibition of recombinant Mycobacterium tuberculosis InhA expressed in Escherichia coli Rosette(DE3) pLysS using trans-2-decenoyl-N-acetylcysteamine as substrate by spectrophotometric method2019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Discovery and development of novel rhodanine derivatives targeting enoyl-acyl carrier protein reductase.
AID1603211Inhibition of Wistar rat kidney ALR1 using sodium D-glucuronate as substrate preincubated for 10 mins followed by substrate addition and measured for 4 mins by spectrophotometric method2019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Designing of acyl sulphonamide based quinoxalinones as multifunctional aldose reductase inhibitors.
AID1713572Inhibition of recombinant human ALR2 using D,L-glyceraldehyde and NADPH as substrate preincubated for 3 mins followed by substrate addition and measured for 3 mins by spectrophotometric analysis2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Pterin-7-carboxamides as a new class of aldose reductase inhibitors.
AID1639207Antitubercular activity against Mycobacterium tuberculosis measured after 48 hrs by luminescence based serial dilution method2019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Discovery and development of novel rhodanine derivatives targeting enoyl-acyl carrier protein reductase.
AID34961Inhibitory activity against purified rat lens aldose reductase (RLAR)1994Journal of medicinal chemistry, Mar-18, Volume: 37, Issue:6
Molecular modeling studies of aldose reductase inhibitors.
AID1589445Inhibition of ALR2 in rat erythrocytes assessed as reduction in sorbitol accumulation at 0.1 uM incubated for 3 hrs in presence of 28 mM glucose by gas chromatographic analysis relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis of new arylsulfonylspiroimidazolidine-2',4'-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress.
AID1338272Inhibition of recombinant human ALR2 assessed as reduction in NADPH oxidation measured for 5 mins in presence of D,L-glyceraldehyde by spectrophotometric method2017European journal of medicinal chemistry, Jan-05, Volume: 125Green fluorescent protein chromophore derivatives as a new class of aldose reductase inhibitors.
AID1589450Inhibition of ALR2 in rat sciatic nerve assessed as reduction in sorbitol accumulation at 0.1 uM incubated for 3 hrs in presence of 28 mM glucose by gas chromatographic analysis relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis of new arylsulfonylspiroimidazolidine-2',4'-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress.
AID643318Selectivity ratio of IC50 for human recombinant AKR1A1 to IC50 for human recombinant AKR1B12012Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1
Design, synthesis, and biological evaluation of novel (1-thioxo-1,2,3,4-tetrahydro-β-carbolin-9-yl)acetic acids as selective inhibitors for AKR1B1.
AID1732116Inhibition of polyol pathway in STZ-induced Kunming mouse model of diabetes assessed as decrease in sorbitol level in kidney cortex at 80 mg/kg, po administered daily via gavage for 8 weeks and measured at 6 hrs post-final drug dose by fluorospectrophotom2021European journal of medicinal chemistry, Apr-05, Volume: 215Multifunctional agents based on benzoxazolone as promising therapeutic drugs for diabetic nephropathy.
AID1298953Antioxidant activity assessed as DPPH free radical scavenging activity at 100 uM after 40 mins by UV-Vis spectrophotometry2016Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12
Synthesis of benzothiadiazine derivatives exhibiting dual activity as aldose reductase inhibitors and antioxidant agents.
AID1678094Selectivity index, ratio of IC50 for rat kidney ALR1 to IC50 for rat lens ALR22020Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20
Dihydrobenzoxazinone derivatives as aldose reductase inhibitors with antioxidant activity.
AID1589449Inhibition of ALR2 in rat erythrocytes assessed as reduction in sorbitol accumulation incubated for 3 hrs in presence of 28 mM glucose by gas chromatographic analysis relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis of new arylsulfonylspiroimidazolidine-2',4'-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress.
AID1366743Inhibition of ALR2 in Wistar rat eye lens assessed as reduction in NADPH consumption preincubated for 1 min followed by D,L-glyceraldehyde addition measured after 4 mins by spectrophotometric analysis2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Structure optimization of tetrahydropyridoindole-based aldose reductase inhibitors improved their efficacy and selectivity.
AID1589452Inhibition of ALR2 in rat sciatic nerve assessed as reduction in sorbitol accumulation at 10 uM incubated for 3 hrs in presence of 28 mM glucose by gas chromatographic analysis relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis of new arylsulfonylspiroimidazolidine-2',4'-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress.
AID1589458Inhibition of ALR2 in rat lens assessed as reduction in sorbitol accumulation at 50 uM incubated for 3 hrs in presence of 28 mM glucose by gas chromatographic analysis relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis of new arylsulfonylspiroimidazolidine-2',4'-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress.
AID1242917Inhibition of Wistar rat ALR2 using D,L-glyceraldehyde as substrate assessed as oxidation of NADPH preincubated for 10 mins followed by substrate addition measured for 4 mins by spectrophotometric analysis2015Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
Phenolic 4-hydroxy and 3,5-dihydroxy derivatives of 3-phenoxyquinoxalin-2(1H)-one as potent aldose reductase inhibitors with antioxidant activity.
AID1772555Inhibition of ALR2 in Wistar rat lens assessed as reduction in NADPH consumption using D,L-glyceraldehyde and NADPH as substrate preincubated for 1 mins followed by substrate addition and measured upto 4 mins by spectrophotometric analysis2021European journal of medicinal chemistry, Nov-05, Volume: 223Non-carboxylic acid inhibitors of aldose reductase based on N-substituted thiazolidinedione derivatives.
AID1678095Inhibition of rat kidney ALR1 using sodium D-glucuronate as substrate preincubated for 4 mins at 37 degC followed by substrate addition and measured after 4 mins in presence of NADPH2020Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20
Dihydrobenzoxazinone derivatives as aldose reductase inhibitors with antioxidant activity.
AID1589442Inhibition of rat kidney ALR1 using DL-glyceraldehyde as substrate and NADPH at 50 uM preincubated for 5 mins followed by substrate addition and measured for 30 mins at 2 mins interval by spectrophotometry relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis of new arylsulfonylspiroimidazolidine-2',4'-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress.
AID516864Inhibition sorbitol dehydrogenase by spectrophotometric analysis2010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
6,7-Dihydroxy-4-phenylcoumarin as inhibitor of aldose reductase 2.
AID1366756Inhibition of ALR2 in Wistar rat lens assessed as reduction in glucose induced-sorbitol accumulation by measuring sorbitol level at 10 uM preincubated for 30 mins followed by glucose addition measured after 3 hrs by resazurin dye based fluorescence assay 2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Structure optimization of tetrahydropyridoindole-based aldose reductase inhibitors improved their efficacy and selectivity.
AID335838Inhibition of aldose reductase in rat lens homogenates by fluorophotometer2002Journal of natural products, Aug, Volume: 65, Issue:8
New flavonol oligoglycosides and polyacylated sucroses with inhibitory effects on aldose reductase and platelet aggregation from the flowers of Prunus mume.
AID641150Inhibition of rat lens aldose reductase using DL-glyceraldehyde as substrate after 30 mins by fluorescence microplate reader analysis2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Antidiabetogenic oligostilbenoids and 3-ethyl-4-phenyl-3,4-dihydroisocoumarins from the bark of Shorea roxburghii.
AID1659473Inhibition of AKR1B1 in rat lenses2020Bioorganic & medicinal chemistry letters, 05-01, Volume: 30, Issue:9
Novel quinolin-4(1H)-one derivatives as multi-effective aldose reductase inhibitors for treatment of diabetic complications: Synthesis, biological evaluation, and molecular modeling studies.
AID1732110Selectivity index, ratio of IC50 for Wistar rat kidney ALR1 to IC50 for Wistar rat lens ALR22021European journal of medicinal chemistry, Apr-05, Volume: 215Multifunctional agents based on benzoxazolone as promising therapeutic drugs for diabetic nephropathy.
AID1589447Inhibition of ALR2 in rat erythrocytes assessed as reduction in sorbitol accumulation at 10 uM incubated for 3 hrs in presence of 28 mM glucose by gas chromatographic analysis relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis of new arylsulfonylspiroimidazolidine-2',4'-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress.
AID1892605Invivo inhibition of ALR2 in STZ-induced diabetic Sprague-Dawley rat model assessed as reduction in ALR2 activity in lens at 80 mg/kg, IG administered once daily for 28 days relative to control2022Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13
Novel Hydroxychalcone-Based Dual Inhibitors of Aldose Reductase and α-Glucosidase as Potential Therapeutic Agents against Diabetes Mellitus and Its Complications.
AID516862Inhibition human recombinant aldose reductase 1 by spectrophotometric analysis2010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
6,7-Dihydroxy-4-phenylcoumarin as inhibitor of aldose reductase 2.
AID1589468Cytotoxicity against HEK293 cells assessed as reduction in cell viability at 100 uM incubated for 48 hrs by MTT assay relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis of new arylsulfonylspiroimidazolidine-2',4'-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress.
AID1589459Inhibition of ALR2 in rat lens assessed as reduction in sorbitol accumulation incubated for 3 hrs in presence of 28 mM glucose by gas chromatographic analysis relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis of new arylsulfonylspiroimidazolidine-2',4'-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress.
AID34964Inhibitory activity measured against rat lens aldose reductase using 3-pyridinecarboxaldehyde as substrate1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
A highly specific aldose reductase inhibitor, ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate, and its congeners.
AID1242919Inhibition of Wistar rat ALR1 using sodium D-glucuronate as substrate assessed as oxidation of NADPH at 10 uM preincubated for 10 mins followed by substrate addition measured for 4 mins by spectrophotometric analysis relative to control2015Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
Phenolic 4-hydroxy and 3,5-dihydroxy derivatives of 3-phenoxyquinoxalin-2(1H)-one as potent aldose reductase inhibitors with antioxidant activity.
AID385353Inhibition of rat lens aldose reductase2008Journal of natural products, Apr, Volume: 71, Issue:4
Erigeroflavanone, a flavanone derivative from the flowers of Erigeron annuus with protein glycation and aldose reductase inhibitory activity.
AID1589467Cytotoxicity against HEK293 cells assessed as reduction in cell viability at 50 uM incubated for 48 hrs by MTT assay relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis of new arylsulfonylspiroimidazolidine-2',4'-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress.
AID748700Oral bioavailability in diabetic neuropathy patient at 150 mg/day2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Progress and developments in tau aggregation inhibitors for Alzheimer disease.
AID1143289Inhibition of bovine aldose reductase assessed as oxidation of NADPH2014European journal of medicinal chemistry, Jun-23, Volume: 81Structure-activity relationships and molecular modelling of new 5-arylidene-4-thiazolidinone derivatives as aldose reductase inhibitors and potential anti-inflammatory agents.
AID489641Selectivity ratio of IC50 for human ALR to IC50 for AKR1B102010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID35131Inhibitory activity against aldose reductase enzyme2003Journal of medicinal chemistry, Jan-30, Volume: 46, Issue:3
Substituted pyrrol-1-ylacetic acids that combine aldose reductase enzyme inhibitory activity and ability to prevent the nonenzymatic irreversible modification of proteins from monosaccharides.
AID1659477Antioxidant activity assessed as DPPH radical scavenging activity at 10 uM relative to control2020Bioorganic & medicinal chemistry letters, 05-01, Volume: 30, Issue:9
Novel quinolin-4(1H)-one derivatives as multi-effective aldose reductase inhibitors for treatment of diabetic complications: Synthesis, biological evaluation, and molecular modeling studies.
AID381852Apparent permeability from serosal to mucosal side in Wistar rat jejunum2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Design and synthesis of N-(3,5-difluoro-4-hydroxyphenyl)benzenesulfonamides as aldose reductase inhibitors.
AID635237Inhibition of Wistar rat lens ALR2 using D,L-glyceraldehyde as substrate after 10 mins by UV/VIS double spectrophotometric analysis2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
1,2-Benzothiazine 1,1-dioxide carboxylate derivatives as novel potent inhibitors of aldose reductase.
AID654332Inhibition of advanced glycation end-products formation after 14 days by spectrofluorimetry2012Journal of natural products, Feb-24, Volume: 75, Issue:2
Chemical constituents from the aerial parts of Aster koraiensis with protein glycation and aldose reductase inhibitory activities.
AID1732108Inhibition of Wistar rat lens ALR2 assessed as reduction in NADPH oxidation using D,L-glyceraldehyde and NADPH as substrate preincubated for 10 mins followed by substrate addition and measured for 4 mins by spectrophotometric analysis2021European journal of medicinal chemistry, Apr-05, Volume: 215Multifunctional agents based on benzoxazolone as promising therapeutic drugs for diabetic nephropathy.
AID1474991Inhibition of goat lenses ALR2 using glyceraldehyde as substrate measured for 5 mins by UV-spectrophotometric method2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Identification of low micromolar dual inhibitors for aldose reductase (ALR2) and poly (ADP-ribose) polymerase (PARP-1) using structure based design approach.
AID1463404Downregulation of laminin levels in rat HBZY-1 cells at 0.3 to 0.9 uM by Western blot analysis2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
1-Acetyl-5-phenyl-1H-pyrrol-3-ylacetate: An aldose reductase inhibitor for the treatment of diabetic nephropathy.
AID1732155Reno-protective activity in STZ-induced Kunming mouse model of diabetes assessed as reduction in urinary total protein excretion at 80 mg/kg, po administered daily via gavage for 8 weeks and measured at week 6 relative to control2021European journal of medicinal chemistry, Apr-05, Volume: 215Multifunctional agents based on benzoxazolone as promising therapeutic drugs for diabetic nephropathy.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID516863Inhibition kidney aldose reductase 2 by spectrophotometric analysis2010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
6,7-Dihydroxy-4-phenylcoumarin as inhibitor of aldose reductase 2.
AID1436863Inhibition of rat kidney ALR1 using sodium D-glucuronate as substrate assessed as decrease in NADPH oxidation at 10 uM preincubated for 10 mins followed by substrate addition measured for 5 mins by spectrophotometer2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
Synthesis and structure-activity relationship studies of phenolic hydroxyl derivatives based on quinoxalinone as aldose reductase inhibitors with antioxidant activity.
AID229528Ratio of IC50 value of rat kidney ALR to rat lens AR1997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
Highly selective aldose reductase inhibitors. 3. Structural diversity of 3-(arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic acids.
AID1463406Cytoprotective activity against HG-induced cell death in rat HBZY-1 cells assessed as increase in apoptosis by measuring late apoptotic cells at 10 uM by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 18.18%)2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
1-Acetyl-5-phenyl-1H-pyrrol-3-ylacetate: An aldose reductase inhibitor for the treatment of diabetic nephropathy.
AID1892579Inhibition of Wistar rat lens ALR2 using D,L-glyceraldehyde as substrate preincubated for 10 mins in presence of NADPH followed by substrate addition and measured after 4 mins2022Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13
Novel Hydroxychalcone-Based Dual Inhibitors of Aldose Reductase and α-Glucosidase as Potential Therapeutic Agents against Diabetes Mellitus and Its Complications.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1732146Reno-protective activity in STZ-induced Kunming mouse model of diabetes assessed as reduction in albumin to creatinine ratio at 80 mg/kg, po administered daily via gavage for 8 weeks2021European journal of medicinal chemistry, Apr-05, Volume: 215Multifunctional agents based on benzoxazolone as promising therapeutic drugs for diabetic nephropathy.
AID1463405Cytoprotective activity against HG-induced cell death in rat HBZY-1 cells assessed as increase in apoptosis by measuring early apoptotic cells at 10 uM by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 8.13%)2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
1-Acetyl-5-phenyl-1H-pyrrol-3-ylacetate: An aldose reductase inhibitor for the treatment of diabetic nephropathy.
AID489639Inhibition of N-terminal 6His-tagged human aldehyde reductase expressed in Escherichia coli BL21(DE3) mediated D-glucuronate reduction2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.
AID1589448Inhibition of ALR2 in rat erythrocytes assessed as reduction in sorbitol accumulation at 50 uM incubated for 3 hrs in presence of 28 mM glucose by gas chromatographic analysis relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis of new arylsulfonylspiroimidazolidine-2',4'-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress.
AID635284Inhibition of Wistar rat kidney ALR1 using D-glucuronate as substrate at 10 uM after 10 mins by UV/VIS double spectrophotometric analysis2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
1,2-Benzothiazine 1,1-dioxide carboxylate derivatives as novel potent inhibitors of aldose reductase.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1589453Inhibition of ALR2 in rat sciatic nerve assessed as reduction in sorbitol accumulation at 50 uM incubated for 3 hrs in presence of 28 mM glucose by gas chromatographic analysis relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis of new arylsulfonylspiroimidazolidine-2',4'-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress.
AID1298962Reduction of MDA level in Wistar rat brain at 100 uM after 30 mins in presence of ascorbic acid by UV-vis spectrophotmetry relative to control2016Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12
Synthesis of benzothiadiazine derivatives exhibiting dual activity as aldose reductase inhibitors and antioxidant agents.
AID1678096Inhibition of rat lens ALR2 using D,L-glyceraldehyde as substrate preincubated for 5 mins at 30 degC followed by substrate addition and measured after 4 mins in presence of NADPH2020Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20
Dihydrobenzoxazinone derivatives as aldose reductase inhibitors with antioxidant activity.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1589454Inhibition of ALR2 in rat sciatic nerve assessed as reduction in sorbitol accumulation incubated for 3 hrs in presence of 28 mM glucose by gas chromatographic analysis2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis of new arylsulfonylspiroimidazolidine-2',4'-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473941Drug concentration at steady state in human at 50 mg, po QD after 24 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID654480Inhibition of Sprague-Dawley albino rat ALR1 assessed as enzyme-mediated oxidation of NADPH using D,L-glyceraldehyde as substrate by spectrophotometric analysis2012European journal of medicinal chemistry, May, Volume: 51Progresses in the pursuit of aldose reductase inhibitors: the structure-based lead optimization step.
AID1659475Antioxidant activity assessed as DPPH radical scavenging activity at 100 uM relative to control2020Bioorganic & medicinal chemistry letters, 05-01, Volume: 30, Issue:9
Novel quinolin-4(1H)-one derivatives as multi-effective aldose reductase inhibitors for treatment of diabetic complications: Synthesis, biological evaluation, and molecular modeling studies.
AID1581670Inhibition of ALR2 in rat lens assessed as reduction in sorbitol accumulation at 50 uM preincubated for 30 mins followed by D-glucose addition and measured after 3 hrs by resazurin based fluorescence analysis relative to control2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Development of Novel Oxotriazinoindole Inhibitors of Aldose Reductase: Isosteric Sulfur/Oxygen Replacement in the Thioxotriazinoindole Cemtirestat Markedly Improved Inhibition Selectivity.
AID489631Inhibition of reductase activity of N-terminal 6His-tagged AKR1B10 expressed in Escherichia coli BL21(DE3) assessed as inhibition of NADPH linked pyridine-3-aldehyde reduction2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.
AID1646336Inhibition of human recombinant AKR1B1 assessed as D,L-glyceraldehyde reduction pretreated with 0.7M DMSO followed by compound addition by DMSO-perturbation assay2020Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2
Early identification of promiscuous attributes of aldose reductase inhibitors using a DMSO-perturbation assay.
AID1589443Inhibition of rat kidney ALR1 using DL-glyceraldehyde as substrate and NADPH preincubated for 5 mins followed by substrate addition and measured for 30 mins at 2 mins interval by spectrophotometry relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis of new arylsulfonylspiroimidazolidine-2',4'-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress.
AID34193In vitro inhibitory activity against rat kidney Aldehyde reductase1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Highly selective aldose reductase inhibitors. 1. 3-(Arylalkyl)-2,4,5-trioxoimidazolidine-1-acetic acids.
AID1892580Inhibition of Wistar rat kidney ALR1 using sodium D-glucuronate as substrate preincubated for 10 mins in presence of NADPH followed by substrate addition and measured after 4 mins2022Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13
Novel Hydroxychalcone-Based Dual Inhibitors of Aldose Reductase and α-Glucosidase as Potential Therapeutic Agents against Diabetes Mellitus and Its Complications.
AID34179Selectivity ratio measured as the IC50 ratio of aldehyde/aldose reductase values1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
A highly specific aldose reductase inhibitor, ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate, and its congeners.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1589444Selectivity ratio of IC50 for rat kidney ALR1 IC50 to IC50 for human recombinant ALR22019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis of new arylsulfonylspiroimidazolidine-2',4'-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress.
AID1197495Inhibition of Wistar rat kidney ALR1 using D,L-glyceraldehyde as substrate preincubated at 10 uM for 10 mins before substrate addition measured after 5 mins by spectrophotometry2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Design and synthesis of potent and multifunctional aldose reductase inhibitors based on quinoxalinones.
AID489638Inhibition of N-terminal 6His-tagged human aldose reductase expressed in Escherichia coli BL21(DE3) mediated NADPH linked pyridine-3-aldehyde reduction2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.
AID1646337Inhibition of AKR1B10 (unknown origin) pretreated with 0.25M DMSO followed by compound treatment by DMSO-perturbation assay2020Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2
Early identification of promiscuous attributes of aldose reductase inhibitors using a DMSO-perturbation assay.
AID1463403Downregulation of collagen 4 levels in rat HBZY-1 cells at 0.3 to 0.9 uM by Western blot analysis2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
1-Acetyl-5-phenyl-1H-pyrrol-3-ylacetate: An aldose reductase inhibitor for the treatment of diabetic nephropathy.
AID603256Inhibition of bovine lens ALR22011European journal of medicinal chemistry, Jul, Volume: 46, Issue:7
Identification of 5-arylidene-4-thiazolidinone derivatives endowed with dual activity as aldose reductase inhibitors and antioxidant agents for the treatment of diabetic complications.
AID1589440Inhibition of human recombinant ALR2 expressed in Escherichia coli using DL-glyceraldehyde as substrate and NADPH at 50 uM preincubated for 5 mins followed by substrate addition and measured after 30 mins at 2 mins interval by spectrophotometry relative t2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis of new arylsulfonylspiroimidazolidine-2',4'-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress.
AID1659474Inhibition of AKR1A1 in rat kidney at 10 uM relative to control2020Bioorganic & medicinal chemistry letters, 05-01, Volume: 30, Issue:9
Novel quinolin-4(1H)-one derivatives as multi-effective aldose reductase inhibitors for treatment of diabetic complications: Synthesis, biological evaluation, and molecular modeling studies.
AID1589455Inhibition of ALR2 in rat lens assessed as reduction in sorbitol accumulation at 0.1 uM incubated for 3 hrs in presence of 28 mM glucose by gas chromatographic analysis relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis of new arylsulfonylspiroimidazolidine-2',4'-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress.
AID643316Inhibition of human recombinant AKR1B1 expressed in Escherichia coli BL21 cells using pyridine-3-aldehyde as substrate by spectrophotometry2012Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1
Design, synthesis, and biological evaluation of novel (1-thioxo-1,2,3,4-tetrahydro-β-carbolin-9-yl)acetic acids as selective inhibitors for AKR1B1.
AID516866Selectivity index, ratio of IC50 for human recombinant aldose reductase 1 to IC50 for kidney aldose reductase 22010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
6,7-Dihydroxy-4-phenylcoumarin as inhibitor of aldose reductase 2.
AID1589441Inhibition of human recombinant ALR2 expressed in Escherichia coli using DL-glyceraldehyde as substrate and NADPH preincubated for 5 mins followed by substrate addition and measured after 30 mins at 2 mins interval by spectrophotometry relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis of new arylsulfonylspiroimidazolidine-2',4'-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress.
AID34192In vitro inhibitory activity against rat kidney aldehyde reductase(ALR).1997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
Highly selective aldose reductase inhibitors. 3. Structural diversity of 3-(arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic acids.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1589451Inhibition of ALR2 in rat sciatic nerve assessed as reduction in sorbitol accumulation at 1 uM incubated for 3 hrs in presence of 28 mM glucose by gas chromatographic analysis relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis of new arylsulfonylspiroimidazolidine-2',4'-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress.
AID1143067Inhibition of Wistar rat eye lens aldose reductase-2 using D-L glyceraldehyde as substrate assessed as oxidation of NADPH preincubated for 10 mins followed by substrate addition measured for 4 mins by spectrophotometric analysis2014European journal of medicinal chemistry, Jun-10, Volume: 80Structure-activity relationships studies of quinoxalinone derivatives as aldose reductase inhibitors.
AID1732109Inhibition of Wistar rat kidney ALR1 assessed as reduction in NADPH oxidation using sodium D-glucuronate and NADPH as substrate preincubated for 10 mins followed by substrate addition and measured for 4 mins by spectrophotometric analysis2021European journal of medicinal chemistry, Apr-05, Volume: 215Multifunctional agents based on benzoxazolone as promising therapeutic drugs for diabetic nephropathy.
AID34806In vitro inhibitory activity against partially purified rat lens Aldose reductase at a dose of 5e-7M1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Highly selective aldose reductase inhibitors. 1. 3-(Arylalkyl)-2,4,5-trioxoimidazolidine-1-acetic acids.
AID401616Inhibition of human muscle recombinant aldose reductase by spectrophotometry2005Journal of natural products, Apr, Volume: 68, Issue:4
Structures and aldose reductase inhibitory effects of bromophenols from the red alga Symphyocladia latiuscula.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1473945Ratio of drug concentration at steady state in human at 50 mg, po QD after 24 hrs to IC50 for human MRP4 overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1772560Selectivity index, ratio of IC50 for ALR1 in Wistar rat kidney to IC50 for ALR2 in Wistar rat lens2021European journal of medicinal chemistry, Nov-05, Volume: 223Non-carboxylic acid inhibitors of aldose reductase based on N-substituted thiazolidinedione derivatives.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID232328Ratio of AR IC50 and ALR IC50 of rat lens and kidney enzyme1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Highly selective aldose reductase inhibitors. 1. 3-(Arylalkyl)-2,4,5-trioxoimidazolidine-1-acetic acids.
AID516865Selectivity index, ratio of IC50 for sorbitol dehydrogenase to IC50 for kidney aldose reductase 22010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
6,7-Dihydroxy-4-phenylcoumarin as inhibitor of aldose reductase 2.
AID1529987Inhibition of human recombinant aldose reductase expressed in Escherichia coli BL21 (DE3) pLysS assessed as reduction in NADPH oxidation using L-idose as substrate2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
An investigation on 4-thiazolidinone derivatives as dual inhibitors of aldose reductase and protein tyrosine phosphatase 1B, in the search for potential agents for the treatment of type 2 diabetes mellitus and its complications.
AID1473942Ratio of drug concentration at steady state in human at 50 mg, po QD after 24 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID232953Inhibitory activity measured against pig kidney aldehyde reductase using 3-pyridinecarboxaldehyde as substrate1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
A highly specific aldose reductase inhibitor, ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate, and its congeners.
AID1473943Ratio of drug concentration at steady state in human at 50 mg, po QD after 24 hrs to IC50 for human MRP2 overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID34795Inhibition of crude aldose reductase of rat lens1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Synthesis and aldose reductase inhibitory activity of substituted 2-oxoquinoline-1-acetic acid derivatives.
AID643319Selectivity ratio of IC50 for recombinant N-His6-tagged AKR1B10 to IC50 for human recombinant AKR1B12012Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1
Design, synthesis, and biological evaluation of novel (1-thioxo-1,2,3,4-tetrahydro-β-carbolin-9-yl)acetic acids as selective inhibitors for AKR1B1.
AID1659476Antioxidant activity assessed as DPPH radical scavenging activity at 50 uM relative to control2020Bioorganic & medicinal chemistry letters, 05-01, Volume: 30, Issue:9
Novel quinolin-4(1H)-one derivatives as multi-effective aldose reductase inhibitors for treatment of diabetic complications: Synthesis, biological evaluation, and molecular modeling studies.
AID643317Inhibition of recombinant N-His6-tagged AKR1B10 expressed in Escherichia coli BL21 cells using pyridine-3-aldehyde as substrate by spectrophotometry2012Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1
Design, synthesis, and biological evaluation of novel (1-thioxo-1,2,3,4-tetrahydro-β-carbolin-9-yl)acetic acids as selective inhibitors for AKR1B1.
AID1589456Inhibition of ALR2 in rat lens assessed as reduction in sorbitol accumulation at 1 uM incubated for 3 hrs in presence of 28 mM glucose by gas chromatographic analysis relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis of new arylsulfonylspiroimidazolidine-2',4'-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress.
AID1202885Inhibition of Wistar rat lens aldose reductase using D,L-glyceraldehyde as substrate incubated for 1 min measured for 4 mins by spectrophotometry2015Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6
Identification of novel aldose reductase inhibitors based on carboxymethylated mercaptotriazinoindole scaffold.
AID709675Inhibition of Sprague-Dawley albino rat lens ALR2 by spectrophotometry2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Benzofuroxane derivatives as multi-effective agents for the treatment of cardiovascular diabetic complications. Synthesis, functional evaluation, and molecular modeling studies.
AID1892583Selectivity index, ratio of IC50 for Wistar rat kidney ALR1 to IC50 for Wistar rat lens ALR22022Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13
Novel Hydroxychalcone-Based Dual Inhibitors of Aldose Reductase and α-Glucosidase as Potential Therapeutic Agents against Diabetes Mellitus and Its Complications.
AID1603214Selectivity index, ratio of IC50 for Wistar rat kidney ALR1 to IC50 for Wistar rat lens ALR22019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Designing of acyl sulphonamide based quinoxalinones as multifunctional aldose reductase inhibitors.
AID34963Inhibitory activity against rat lens aldose reductase(AR).1997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
Highly selective aldose reductase inhibitors. 3. Structural diversity of 3-(arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic acids.
AID549694Inhibition of bovine lens aldose reductase assessed as inhibition of NDAPH oxidation by non-linear regression analysis2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
In vitro evaluation of 5-arylidene-2-thioxo-4-thiazolidinones active as aldose reductase inhibitors.
AID1603210Inhibition of Wistar rat lens ALR2 using L-glyceraldehyde as substrate preincubated for 10 mins followed by substrate addition and measured for 4 mins by spectrophotometric method2019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Designing of acyl sulphonamide based quinoxalinones as multifunctional aldose reductase inhibitors.
AID1646335Inhibition of human recombinant AKR1B1 assessed as D,L-glyceraldehyde reduction pretreated with 0.3M DMSO followed by compound addition by DMSO-perturbation assay2020Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2
Early identification of promiscuous attributes of aldose reductase inhibitors using a DMSO-perturbation assay.
AID1732154Reno-protective activity in STZ-induced Kunming mouse model of diabetes assessed as reduction in urinary total protein excretion at 80 mg/kg, po administered daily via gavage for 8 weeks and measured at week 4 relative to control2021European journal of medicinal chemistry, Apr-05, Volume: 215Multifunctional agents based on benzoxazolone as promising therapeutic drugs for diabetic nephropathy.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1473940AUC in human at 50 mg, po QD after 24 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID654479Inhibition of Sprague-Dawley albino rat ALR2 assessed as enzyme-mediated oxidation of NADPH using D,L-glyceraldehyde as substrate by spectrophotometric analysis2012European journal of medicinal chemistry, May, Volume: 51Progresses in the pursuit of aldose reductase inhibitors: the structure-based lead optimization step.
AID1646338Inhibition of AKR1B10 (unknown origin) pretreated with 0.42M DMSO followed by compound treatment by DMSO-perturbation assay2020Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2
Early identification of promiscuous attributes of aldose reductase inhibitors using a DMSO-perturbation assay.
AID381853Ratio of permeability from mucosal to serosal over serosal to mucosal side of the Wistar rat jejunum2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Design and synthesis of N-(3,5-difluoro-4-hydroxyphenyl)benzenesulfonamides as aldose reductase inhibitors.
AID1589469Cytotoxicity against HEK293 cells assessed as reduction in cell viability at 200 uM incubated for 48 hrs by MTT assay relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis of new arylsulfonylspiroimidazolidine-2',4'-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1060596Inhibition of rat kidney NADPH-dependent aldose reductase assessed as DL-glyceraldehyde conversion to glycerol preincubated for 20 mins followed by NADPH addition measured after 5 mins by UV-Visible spectrophotometric analysis2014European journal of medicinal chemistry, Jan, Volume: 71Synthesis and biological evaluation of new epalrestat analogues as aldose reductase inhibitors (ARIs).
AID1732151Antidiabetic activity in STZ-induced Kunming mouse model of diabetes assessed as reduction in blood glucose level at 80 mg/kg, po administered QD via gavage for 4 weeks and measured at week 2 to 42021European journal of medicinal chemistry, Apr-05, Volume: 215Multifunctional agents based on benzoxazolone as promising therapeutic drugs for diabetic nephropathy.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (224)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (5.80)18.7374
1990's58 (25.89)18.2507
2000's46 (20.54)29.6817
2010's73 (32.59)24.3611
2020's34 (15.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 54.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index54.50 (24.57)
Research Supply Index5.58 (2.92)
Research Growth Index5.12 (4.65)
Search Engine Demand Index87.83 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (54.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials22 (9.05%)5.53%
Reviews20 (8.23%)6.00%
Case Studies3 (1.23%)4.05%
Observational0 (0.00%)0.25%
Other198 (81.48%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effects of Epalrestat on Peripheral Neuropathy and Central Nervous System in Diabetic Patient [NCT05184049]Phase 472 participants (Anticipated)Interventional2022-01-31Recruiting
Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer:A Single Arm,Single Center,Phase II Study [NCT03244358]Phase 212 participants (Actual)Interventional2017-03-01Terminated(stopped due to Difficulty accruing subjects the study accrual was closed)
Multi-center Study of Natural History of SORD-related Charcot-Marie-Tooth Disease and Epalrestat Treatment [NCT05777226]Phase 230 participants (Anticipated)Interventional2023-04-30Not yet recruiting
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of Oral Epalrestat Therapy in Pediatric Subjects With Phosphomannomutase 2-congenital Disorder of Glycosylation (PMM2-CDG) [NCT04925960]Phase 340 participants (Anticipated)Interventional2022-11-10Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]